Clin2
NCT07766499Possibly a fitNot yet recruiting

Study of an experimental drug for chronic hives

Chronic Spontaneous Urticaria (CSU)Chronic Idiopathic Urticaria

Part of Immune system & allergy, Skin clinical trials.

This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
81 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You are between 18 and 85 years old.
  • You have had hives for at least 6 months, with symptoms still present despite taking an antihistamine (like Zyrtec or Claritin).
  • You have had a certain level of hives and itching in the week before starting the study, as measured by a daily diary.
  • Your weight and body mass index (BMI) must be within a specific range.
  • You are willing to fill out a daily electronic diary and attend study visits.
  • You must agree to use birth control if you are able to become pregnant or father a child.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07764003Not yet recruiting· Phase 2
Study of a new pill for chronic hives despite antihistamines

This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.

NCT07665996Not yet recruiting· Phase 1/Phase 2
TLL-018 for chronic hives not helped by antihistamines

This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.

Chengdu, Sichuan
NCT07378527Recruiting· Phase 2/Phase 3
Study of ICP-332 for chronic hives not helped by antihistamines

This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.

Bengbu, Anhui
NCT07166211Recruiting· Phase 2
Study of CM512 injection for chronic hives

This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.

Tianjin, Tianjin Municipality
NCT07684560Not yet recruiting· Phase 1
Study of Alpha-0261 tablets for chronic hives

This trial tests a new tablet (Alpha-0261) for chronic spontaneous urticaria (long-lasting hives without a clear cause). It aims to see if the drug is safe and tolerable. Part 1 includes people with chronic hives, and Part 2 looks at how food affects the drug in healthy adults.

Beijing, Beijing Municipality
NCT07546487Not yet recruiting· Phase 3
Testing MG-K10 for chronic hives that don't respond to allergy pills

This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.

Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.